⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma

Official Title: An Open-label Phase 1b Study of ORIC-533 in Patients With Relapsed or Refractory Multiple Myeloma

Study ID: NCT05227144

Interventions

ORIC-533

Study Description

Brief Summary: The purpose of this study is to establish the Recommended Phase 2 Dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antimyeloma activity of ORIC-533 in patients with multiple myeloma who have exhausted available treatment options

Detailed Description: ORIC-533 is a selective, orally bioavailable, small molecule inhibitor of CD73.This is an open-label, uncontrolled, multicenter, dose-finding study to assess the safety and preliminary antimyeloma activity of ORIC-533 in patients with relapsed or refractory multiple myeloma. After the RP2D has been determined, dose expansion will further evaluate safety and preliminary antimyeloma activity of ORIC-533 in patients with relapsed or refractory multiple myeloma.

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

James R. Berenson, MD, Inc., West Hollywood, California, United States

Northside Hospital Cancer Institute, Atlanta, Georgia, United States

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Mayo Clinical Rochester, Rochester, Minnesota, United States

Icahn School of Medicine at Mount Sinai, New York, New York, United States

The Charlotte-Mecklenburg Hospital Authority d/b/a Atrium Health, Charlotte, North Carolina, United States

Swedish Health Services, Seattle, Washington, United States

Princess Margaret Cancer Research Center/University Health Network, Toronto, Ontario, Canada

Contact Details

Name: Pratik S. Multani, MD

Affiliation: ORIC Pharmaceuticals

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: